Description

Delmitide (RDP58) is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide can be used for the research of ulcerative colitis[1][2].—COVID-19-immunoregulation–C59H105N17O11—-[1]Arthur Kaser, et al. Novel therapeutic targets in the treatment of IBD. Kaser, Arthur; Tilg, Herbert (2008). Expert Opinion on Therapeutic Targets, 12(5), 553–563. |[2]Jingsong Zhao, et al. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res. 2004 Apr 15;10(8):2851-9. –287096-87-1–1228.57—-N=C(N)NCCC[C@@H](N)C(N[C@H](CCCC)C(N[C@H](CCCC)C(N[C@H](CCCC)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCC)C(N[C@H](CCCC)C(N[C@H](CCCC)C(NCC(N[C@@H](C(N)=O)CC1=CC=C(C=C1)O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cancer; Infection; Inflammation/Immunology–10 mM in DMSO–IFNAR;Reactive Oxygen Species;TNF Receptor—-Apoptosis;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB–Peptides